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The Saguenay–Lac St-Jean population of Quebec is relatively isolated and has genealogical records dating to the
17th-century French founders. In 120 extended families with at least one sib pair affected with early-onset hyper-
tension and/or dyslipidemia, we analyzed the genetic determinants of hypertension and related cardiovascular and
metabolic conditions. Variance-components linkage analysis revealed 46 loci after 100,000 permutations. The most
prominent clusters of overlapping quantitative-trait loci were on chromosomes 1 and 3, a finding supported by
principal-components and bivariate analyses. These genetic determinants were further tested by classifying families
by use of LOD score density analysis for each measured phenotype at every 5 cM. Our study showed the founder
effect over several generations and classes of living individuals. This quantitative genealogical approach supports
the notion of the ancestral causality of traits uniquely present and inherited in distinct family classes. With the
founder effect, traits determined within population subsets are measurably and quantitatively transmitted through
generational lineage, with a precise component contributing to phenotypic variance. These methods should accelerate
the uncovering of causal haplotypes in complex diseases such as hypertension and metabolic syndrome.
Introduction
Hypertension, present in 10%–35% of humans, is one
of the principal risk factors for cardiovascular disease
in the United States, Canada, and other industrialized
nations (Franklin et al. 2001; Joffres et al. 2001). To-
gether with obesity and dyslipidemia, it represents a sig-
nificant proportion of the global and regional burden of
diseases (Ezzati et al. 2002). These three entities are fre-
quently present together and are cardinal features of the
metabolic syndrome (Reaven 2004). The absence of such
phenotypes is associated with longevity in the offspring
of centenarians (Atzmon et al. 2004). With the impend-
ing pandemic of obesity, the increasing prevalence of
these conditions will contribute to the worldwide prom-
inence of cardiovascular mortality by 2020 (Groop and
Orho-Melander 2001). The etiologies of these entities
are usually multifactorial and the result of polygenic
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interactions with the environment (Hamet et al. 1998;
Pausova et al. 1999). Although effective treatments are
available for hypertension and dyslipidemia (Turnbull
and Blood Pressure Lowering Treatment Trialists’ Col-
laboration 2003), they do not address the potential
causal concomitance of presentation that may, by itself,
provide novel therapeutic and preventive targets.
Since tools for the resolution of polygenic diseases are
now available (Lander and Schork 1994; Doris 2002),
several studies have reported genomewide scans for hy-
pertension (Caulfield et al. 2003; Jacobs et al. 2003;
James et al. 2003; Ranade et al. 2003; von Wowern et
al. 2003), obesity, and dyslipidemia (Loos et al. 2003;
Stein et al. 2003; Tang et al. 2003; Langefeld et al. 2004;
Ueno et al. 2004), adding to a much earlier and more
complete resolution of the monogenic forms of hyper-
tension (Lifton et al. 2001). However, the results have
usually been limited to a few QTLs with marginally
significant LOD scores and a modest contribution to
overall trait variance (Samani 2003)—even the results
from a recent meta-analysis of 6,245 relatives from four
multicenter networks of the Family Blood Pressure Pro-
gram (Province et al. 2003). The most common limiting
factors include genetic and environmental heterogeneity,
which lead to decreased statistical power (Glazier et al.
2002). The present study proposes an integrative ap-
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proach to the resolution of complex traits. We chose
hypertension and dyslipidemia as the ascertainment cri-
teria. Furthermore, we conducted our studies on French
Canadians who represent a homogeneous population
who had large families until the 1940s and who, more
importantly, have computerized genealogical records
dating to the original 17th-century settlers (Bouchard
et al. 1989; Heyer and Tremblay 1995). With a method
similar to our physiological genomics strategy that was
applied to a human cohort of African Americans (Kot-
chen et al. 2002) and to rodent models (Stoll et al.
2001), we have used an integrated multisystem phe-
notyping protocol to ascertain the characteristics of car-
diovascular, renal, metabolic, and anthropometric fea-
tures, under stringent standard operating procedures.
We report that QTLs for several components of the
metabolic syndrome are clustering within the same ge-
nomic regions. By extending sequential oligogenic link-
age analysis routine (SOLAR)–corrected LOD (LODcor)
scores through density analysis, we were able to define
sets of families with distinct contributions to several
traits. A novel layered-founder approach strongly un-
derlined the finding of ancestral causality by the dem-
onstration of founder separability. These observations
permit us to propose a “quantitative founder effect” in
complex diseases.
Methods and Procedures
Family Cohort
Families were recruited from a relatively genetically
differentiated population in the Saguenay–Lac St-Jean
(SLSJ) area of the Canadian province of Quebec. Fam-
ilies were ascertained by the presence of at least one sib
pair with hypertension and dyslipidemia. Sibship sizes
ranged from 2 to 11 persons (mean 3.9; median 3). The
affected sib pair–inclusion criteria were essential hyper-
tension (systolic blood pressure [SBP] 1140 mmHg and/
or diastolic blood pressure [DBP] 190 mmHg on two
occasions or the use of antihypertensive medication),
dyslipidemia (plasma cholesterol 5.2 mmol/liter and/
or HDL cholesterol 0.9 mmol/liter or the use of lipid-
lowering medication), BMI !35 kg/m2, age 18–55 years,
and Catholic French Canadian origin. Exclusion crite-
ria included secondary hypertension, DBP 1110 mmHg
and the use of medication, diabetes mellitus, renal or
liver dysfunction, malignancy, pregnancy, and substance
abuse. Once the affected sib pairs were selected, all first-
and second-degree relatives aged 118 years were invited
to participate in the study, independent of health status.
The recruited population included 120 families (mean
size 7.3 persons; median size 5 persons), comprising 897
subjects and 1,617 sib pairs (259 concordant-affected,
556 discordant, and 802 nonaffected sib pairs).
Family structure was tested for consistency by cal-
culating the probabilities of relatedness on the basis of
the genotype data (M. J. Daly, personal communication).
Because of the results of paternity analysis, two subjects
were removed prior to linkage analysis. The SOLAR
software package (version 1.7.3) was used to calculate
multipoint identity by descent (MIBD) for all subjects.
Errors detected by SOLAR were resolved by a review of
the genotypes of subjects and/or pedigrees, after which
14 genotypes from 10 subjects were removed because
of genotype data inconsistency (mostly due to mistyp-
ing). Pedigree and subject genotype reviews continued
in an iterative process until MIBDs were calculated with
no error messages.
The study was approved by the ethics committees at
Complexe Hospitalier de la Sagamie (Chicoutimi, Que-
bec), Universite´ du Que´bec a` Chicoutimi, and the Centre
hospitalier de l’Universite´ de Montre´al.
Phenotyping
All phenotyping was performed by trained personnel
who followed standard operating procedures (Kotchen
et al. 2000, 2002; Pausova et al. 2000, 2002). Restricted
phenotyping on day 0 included taking blood samples for
DNA extraction and measuring plasma lipid, fasting glu-
cose, uric acid, sitting blood pressure (BP), and bioim-
pedance (RJL System) to determine water distribution
and body fat mass. Anthropometric data included 3
global measures of obesity—BMI and percentage body
fat (%body fat) derived from skinfolds and from bioim-
pedance—and 11 regional measures: 6 trunk and ex-
tremity circumferences and 5 skinfolds. Subjects without
any contraindications were invited for extensive phe-
notyping and had their antihypertensive drugs with-
drawn for 1 wk and lipid-lowering agents withdrawn
for 1 mo. From 499 hypertensive subjects studied, 388
were receiving medication, which was stopped for the
purposes of full phenotyping in 135 hypertensive sub-
jects. Full phenotyping was performed for a total of 294
normotensive and hypertensive individuals.
On day 1 of extensive phenotyping, an intravenous
catheter was inserted. Fasting samples were taken for
the measurement of lipid, glucose, and insulin concen-
trations. A postural test was conducted for 60 min in
the supine position followed by 10 min standing and 20
min sitting, while cardiac functions (by impedance ple-
thysmography [SORBA Medical System]) and BP (Dy-
namap, Johnson and Johnson Medical) were monitored.
Both impedance and BP were then measured after mental
stress of mathematical tests (McAdoo et al. 1990). In-
sulin sensitivity was tested with Bergman’s minimal
model, and insulin sensitivity and glucose effectiveness
were quantified as described elsewhere (Steil et al. 1993).
At the end of day 1, 24-h BP monitoring was initiated.
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On day 2, BP, renal blood flow by p-aminohippuric acid
clearance, and glomerular filtration rate by inulin clear-
ance were measured at baseline and after stepwise nor-
epinephrine infusion of 0.01–0.05 mg/kg/min (Kotch-
en et al. 2000). Patients received a water load of 15 ml/
kg plus normal saline intravenously over a 6-h period.
Plasma arginine-vasopressin, atrial natriuretic factor, cy-
clic nucleotide (cGMP and cAMP) concentrations, and
renin activity were quantified at baseline and after flu-
id challenge. Cardiac echographic measurements were
taken on a different day.
Among all phenotypes, those that were measured and
analyzed included 3 anthropometric, 3 plasma, 37 BP,
12 time-series BP, 14 cardiac (cardiac output and index),
46 impedance plethysmography, 6 echocardiography, 19
heart rate, 32 neuroendocrine, 22 renal, and 28 plethys-
mography-related measures. Each phenotype was tested
for normality of distribution by kurtosis and skewness
and by the Kolmogorov-Smirnov test. When kurtosis
was 12, values were normalized by simple function
transformation (i.e., transformed by log, square root, or
power) (Blangero et al. 2001) and were further analyzed
to decrease the likelihood of false-positive errors (e.g.,
by variance-components, covariance, principal-compo-
nents, and bivariate analyses). Power transformation
was the first choice for any phenotype containing neg-
ative numbers (e.g., delta-calculated values). All three
transformations were tested, and we used the one that
achieved normality without excessive loss of data points.
As in the analyses by Allison et al. (1999), we accepted,
on rare occasions, slight deviations from normality if it
could be assumed that they would not affect the LOD
score substantially. Most importantly, however, we ran
100,000 simulations to correct for such deviations from
normality and to test the robustness of our results. This
method is considered to be one of the best ways to deal
with normality issues. When more than two groups were
compared, one- or two-way analysis of variance was
applied post hoc using the Tukey honest significance dif-
ference test for specific pairs of variables. The null hy-
pothesis was rejected whenever P was !.05. Phenotype
analysis screened for general covariates, including sex,
age, and BMI, with stepwise removal of each covariate
to test its significance.
Genotyping
DNA samples from the first 500 recruited subjects
originating from 97 families were genotyped at the
Broad Institute (formerly the Whitehead Institute for
Biomedical Research/MIT Center for Genome Re-
search), by use of 377 microsatellite markers, with a
modified version of the Cooperative Human Linkage
Center Screening Set (version 6.0) that included Gene-
thon markers for an average of 9.1-cM coverage of the
entire human genome. Details of the genotyping system
can be found elsewhere (Rioux et al. 1998). Additional
markers (Genethon) at a 5-cM density were used on
chromosome (chr) 1q and chr 3q in a total of 810 sub-
jects. Post hoc analysis determined a genotyping error
rate of ∼0.016%.
Components of Total Variance
We estimated the individual contribution of QTLs to
the trait variance. Other modeled effects included re-
sidual effects (including environmental effects) and the
effects of the covariates age and sex. For these analyses,
we used extended families (i.e., those not split into sib
pairs). We performed oligogenic segregation analyses
based on reversible-jump Bayesian Markov Chain–
Monte Carlo (MCMC) methods and implemented in the
computer program Loki, version 2.4.5 (available at the
Pangaea Web site), as described elsewhere (Heath 1997;
Daw et al. 1999; Gagnon et al. 2003).
These MCMC methods estimate model parameters,
including the number of QTLs and their contribution to
the trait variance, given the assigned prior distributions
for each parameter in the model and the current states
of all other model parameters. We applied Poisson prior
distribution with a mean of 1 for the number of QTLs.
We investigated several values for the prior variance
of genotype effects. The choice of the best value for
the genotype effects was based on the guidelines pro-
posed by Wijsman (2002). For these analyses, posterior
parameter estimates were based on average values of
501,000 iterations of this process, with every second
iteration saved for computation. The first 1,000 itera-
tions were discarded to allow for initial burn-in of the
MCMC process. Several runs were performed, and the
results from one representative run for each trait are
presented in this article. Since the Bayesian MCMC
methods were not based on a hypothesis-testing frame-
work, P values could not be estimated.
Permutation Analysis
To test for LOD robustness, a simulation method for
permutation analysis was implemented with SOLAR
(Blangero et al. 2001). LOD adjustment was computed
with the LODadj command, which runs a simulation of
the distribution of LOD scores that can be expected
under the null hypothesis of no linkage. We ran 100,000
trials, and, in each trial, a fully informative marker,
completely unlinked to the trait, was simulated and the
trait linkage was tested. Under the assumption of mul-
tivariate normality, the theoretical null distribution is
well known. The LODadj command regresses the ob-
served LOD scores on the LOD scores expected for a
multivariate normal trait. The inverse of the slope of the
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Figure 1 Example of a LOD score density plot. Three regions
can be observed in the density function. The figure legend is available
in its entirety in the online edition of The American Journal of Human
Genetics.
regression line is the LOD adjustment. Adjusted LOD
scores are reported here.
Principal-Components and Bivariate Analyses
Principal-components analysis (PCA) is a multivariate
statistical method that allows the formulation of quan-
titatively informative linear combinations of correlated
phenotypes by maximizing phenotypic or familial var-
iance—and thus reducing the number of tests per-
formed—by exploring only the proper linear combina-
tions in further variance-components analyses. It is
extremely effective for correlated phenotypes regulated
by a common locus, and it increases the power signif-
icantly. Hence, PCA is applied to maximize the total
variance. Eigen pairs of the covariance matrix account-
ing for 95% of the variance formed the principal
components.
Both bivariate analysis and PCA can increase the
power of analysis in a case of phenotypes with small or
negatively correlated environmental factors and with
strong genetic correlation. Although bivariate analysis
explicitly models the cross correlation matrix, it also
adds more parameters into the model and makes the
computations extensive. On the other hand, PCA re-
duces the number of tests by providing linear combi-
nations of maximum variance for further analysis.
Hence, both methods can make valuable contributions.
LOD Score Density Analysis
Density functions are the integral or discrete sum of
other function values over a ranked set of function ar-
guments. A discrete example of density d over function
f is
f:N r R
d:N r R
d(x)p f(u) ,
ux
where x and v are the integer arguments of functions d
and f, N is the set of integer numbers, and R is the set
of real numbers.
LOD score density can be computed on the basis of
the LOD score contribution (LODC) of individual ped-
igrees, which are families in this case, as follows:
d(FAM )p LOD (FAM ) ,i C j
FAM /FAM FAMj j i
where
(FAM  FAM )⇔j i
[LOD (FAM ) 1 LOD (FAM )]∨C j C i
([LOD (FAM )p LOD (FAM )]∧ [j  i])C j C i
and where ∨ is the logic “OR” operator, ∧ is the logic
“AND” operator, and i and j are family identifiers.
In other words, LOD score density d is computed for
families ranked by decreasing values of LOD score con-
tribution, LODC, as supplied by SOLAR from FAM i
through . In the case of equal LOD contribution,FAM j
the identifiers of families are arbitrarily considered for
the purposes of ordering. In this context, density can
also be interpreted as an incremental LOD score com-
putation, in which families are incrementally added
to the population in decreasing order of LOD score
contribution.
An example of a LOD score density plot is reported
in figure 1. LOD density represents the LOD score values
that would be obtained if the population were restricted
to families for which the density is computed. In figure
1, we can observe three regions in the density function:
an initial region in which the LOD score increases as
families are added to the population, a somehow stable
region in which adding families does not significantly
change the LOD value, and a final region in which add-
ing families decreases the LOD score. We name the fam-
ilies belonging to these three regions “contributing”
families (CF), “noncontributing” families (NCF), and
“anticontributing” families (ACF), respectively. The
families belonging to these regions can be used to assess
whether they can be statistically distinguished by certain
phenotypes and markers.
Quantitative Founder Effect
A population is considered subject to a founder effect
when a few ancestors from a set F of founders account
for most of the genetic contribution to a set S of de-
scendants. In this context, founders can be ranked on
the basis of their nonuniform genetic contribution, from
the highest to the lowest contributions.
An example of the genetic contribution of founders
appears in figure 2A, whereas figure 2B reveals the con-
stant genetic contribution for the contrasting hypothesis
of a uniform contribution of founders. The density d of
genetic contributions is shown in figure 2C for a pop-
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Figure 2 Graphs of genetic contribution and density of genetic
contribution. The figure legend is available in its entirety in the online
edition of The American Journal of Human Genetics.
ulation subject to the founder effect, whereas figure 2D
displays the density in the case of uniform distribution.
In this context, density can also be interpreted as an
incremental genetic contribution computation when
founders are incrementally considered in decreasing or-
der of genetic contribution.
Qualitatively, a more convex shape of genetic contri-
bution density indicates that a smaller group of founders
contributes to most of the genetic pool of a population.
Extreme diagrams of genetic contribution density are
single-founder diagrams, which result in a horizontal
line corresponding to total genetic contribution , andgcT
uniform-founder diagrams, which are depicted as a di-
agonal line from 0 to . Usual cases produce convexgcT
diagrams between the two extremes.
Quantitatively, the shape of genetic contribution den-
sity function d can be expressed by its average value
n1—
dp # d , in ip1
where n is the number of density values. When the num-
ber of founders n is large enough, varies approximately
—
d
between and , corresponding to the cases ofgc /2 gcT T
uniform- and single-founder contributions, respectively.
In rigorous language, uniform genetic distribution den-
sity is a ladder function with steps of , whose1/n# gcT
average value is discussed in more detail in appendix A
(online only).
We call founder-effect measure fe the normalized dif-
ference between and the average uniform contribution
—
d
density, as described more precisely in appendix A (on-
line only). The founder-effect measure varies between 0
and 1, and it is equal to 0 when the founders’ genetic
contributions are exactly uniformly distributed, whereas
it is equal to 1 when only one founder contributes to
the genetic pool.
The founder-effect measure gives an indication of the
polarization and concentration of the genetic contribu-
tion from a limited number of founders. It can be used
to study, in absolute terms, genetic transmission in dif-
ferent genealogies, or, within the same genealogy, it can
compare different subpopulations with respect to the
same set of founders or compare different sets of foun-
ders with respect to the same subpopulation.
Layered Founders: Ancestral Separability Method
The genetic pool of the SLSJ population included in
our analysis reflects its demographic history. It was
shaped by its very early founders, starting in 1675 in
the Charlevoix settlement and followed by migration to
the SLSJ region. Until 1870, 180% of the SLSJ popu-
lation came from Charlevoix, and 70% were descen-
dants of the first three migration waves (Labuda et al.
1996). The rapid growth of the population was the result
of the very large family sizes in each generation. The
contribution of the later migration waves to the genetic
pool diminished significantly with each generation. Such
population characteristics led us to use a “genealogical
graph” in which edge direction represents generational
steps. We developed the layered-founder approach to
overcome distortions discussed by E. Merlo, B. Deslau-
riers, G. Antoniol, P. L. Brunelle, M. Jomphe, G. Bou-
chard, O. Seda, U. Broeckel, A. W. Cowley Jr., J. Trem-
blay, and P. Hamet (unpublished data). Founders who
share a common distance from today’s individuals con-
stitute a layer within the geometric analogy to the con-
cept. The first layer is the set of parents of the studied
individuals, the second is that of grandparents, and so
on, until the beginning of the colony. Two ancestors vi
and belong to the same layer if they are at the samev Lkj
distance k from today’s population, as follows:
u , u  L ↔ distance(u )p distance(u )p k .i j k i j
In a given genealogy, several layers of founders can
be identified, depending on the different k values of dis-
tance from today’s individuals. Since the number of gen-
erations between an ancient founder and today’s pop-
ulation may vary, it is possible that the maximum
number of generations and the maximum number of
computed layers do not coincide. Furthermore, layers
also depend on the definition of distance. In work by E.
Merlo, B. Deslauriers, G. Antoniol, P. L. Brunelle, M.
Jomphe, G. Bouchard, O. Seda, U. Broeckel, A.W. Cow-
ley Jr., J. Tremblay, and P. Hamet (unpublished data),
several definitions of distances and layers are presented,
evaluated, and discussed. The definition used in the pre-
sent article is constrained average distance layered foun-
ders. Founders are specific to the class to which their
genetic contribution is higher. For example, we can de-
termine the set of founders from a layer whose iden-Lk
tical-by-descent probability p to CF is higher than their
p to ACF by using a maximum-likelihood classification
scheme, and we label them as “CF-specific” founders.
Similarly, we can compute the mutually exclusive set of
founders specific to ACF. In conceptual terms,
p(f/CF) 1 p(f/ACF) r f  {CF-specific founders} .
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Figure 3 Schematic illustration of separability and specificity of
layered founders with respect to distinct classes of families in the cur-
rent generation.
Technically, the previous equation has to be further
detailed, as presented in work by E. Merlo, B. Deslau-
riers, G. Antoniol, P. L. Brunelle, M. Jomphe, G. Bou-
chard, O. Seda, U. Broeckel, A.W. Cowley Jr., J. Trem-
blay, and P. Hamet (unpublished data). Although, in
absolute terms, specific founders genetically contribute
to one class of descendants more than to another, the
difference of contributions may be irrelevant. Indeed,
there are few founders for whom the gene-transmission
probability to both classes is identical. Thus, a new mea-
sure called “separability” has been introduced to capture
the relevance of the difference in gene-transmission prob-
ability. In conceptual terms,
n1 1 [ ]separabilityp gc(f /CF) gc(f /ACF) i i(2 n ip1
m1 [ ] gc(f /ACF) gc(f /CF) , j j )m jp1
where n founders in layer are specific to CF andf Li k
m founders are specific to ACF. Separability can befi
thought of as the average difference in genetic contri-
bution observed for the two sets of founders specific to
either CF or ACF classes. Again, the previous equation
has to be further detailed, as presented in work by E.
Merlo, B. Deslauriers, G. Antoniol, P. L. Brunelle, M.
Jomphe, G. Bouchard, O. Seda, U. Broeckel, A.W. Cow-
ley Jr., J. Tremblay, and P. Hamet (unpublished data).
The separability and specificity of layered founders with
respect to distinct classes of families in the current gen-
eration are illustrated schematically in figure 3.
Results
General Characteristics of Subjects
BP, anthropometric, and selected metabolic data val-
idated in 810 subjects at the time of analysis are reported
in table 1, which also identifies traits that are highly
significantly different between hypertensive and nor-
motensive subjects of both sexes. These involve BP, as
expected, and several anthropometric parameters, in-
cluding %body fat, particularly as derived from impe-
dance measurements. Noticeably, %body fat determined
by impedance correlated significantly with %body fat
calculated by skinfolds ( ; ), whereasrp 0.70 P ! .001
the difference between normotensive and hypertensive
subjects was better captured by impedance.
Table 1 also reports familial correlations and estimates
of apparent heritability (h2) calculated by the FCOR
program of the SAGE statistical package. Significant
correlations within sib pairs ( and ;2h p 2xr r 1 0.25
therefore, ) were found for SBP, DBP, and heart2h 1 50%
rate only in normotensive individuals of both sexes. It
must be noted, however, that apparent heritability es-
timates for BP were much higher for hypertensive sub-
jects ( ) after the withdrawal of antihypertensivenp 174
medications, increasing in males from torp 0.03 rp
for SBP and from to for DBP0.29 rp 0.01 rp 0.22
and in females from to for SBP andrp 0.04 rp 0.35
from to for DBP, regardless ofrp 0.14 rp 0.37
whether the analysis included those who were never
treated for hypertension ( ). As reported else-np 293
where, anthropometric measures, particularly those re-
lated to higher %body fat, exhibited higher heritability
percentages in hypertensive than in normotensive sub-
jects (Pausova et al. 2001). This was also evident for
heritability estimates of serum glycerol levels (table 1).
Partitioning of Variance
To evaluate the feasibility of detecting and mapping
QTLs underlying the hemodynamic, anthropometric,
and metabolic traits presented in table 1, we targeted
the traits with high heritability by estimating the number
of large QTLs and their relative contributions to the
variance for traits (table 2).
Estimates of variance contribution for the effects mod-
eled (table 2) showed evidence of at least one major QTL
with individual contribution in the range of 18% to
141% for several traits. There was also evidence of a
second QTL with a large effect, up to ∼25% contri-
bution, for some of these traits. Subscapular skinfolds
presented evidence of the highest genetic contribution,
with at least three QTLs, each with an individual con-
tribution 120%. Our results also suggest a large con-
tribution (∼18%) of age to the variance of SBP but not
DBP, which is compatible with the well-known contin-
uous increase in SBP with aging, in contrast to DBP,
which reaches a plateau and then declines after age 55
years, as seen in this population and in a population
study of 27,000 Canadians (Joffres et al. 2001), with
findings similar to data from the Framingham Heart
Study (Franklin 2004) and National Health and Nutri-
tion Examination Survey III (Burt et al. 1995). Age was
found to contribute, to a large extent, to the variance
of %body fat measured by impedance. On the other
hand, the covariate sex explained 12%–24% of the var-
iance of waist circumference, LDL levels, and %body
fat. These results thus confirmed that age and sex are
Table 1
Biological Characteristics and Familial Correlations of Phenotypes, by Patient Sex and BP Status
CHARACTERISTICa
MALES FEMALES
With HBP
( b)np 205
Without HBP
( c)np 166
With HBP
( d)np 262
Without HBP
( e)np 177
Mean SE r Mean SE r Mean SE r Mean SE r
Age (years) 51.53 .83 45.30 1.07 57.37 .74 42.92 1.05
SBP (mmHg) 142.0 1.6 .03 121.9 1.0 .29 144.2 1.4 .04 113.7 1.0 .13
DBP (mmHg) 90.6 .8 .01 78.6 .7 .33 84.8 .7 .14 73.5 .7 .24
Heart rate (beats/min) 70.7 1.1 .07 67.6 1.0 .55 73.6 .9 .00 72.7 .8 .53
Height (cm) 171.0 .5 .56 173.5 .5 .68 157.6 .4 .46 160.3 .5 .47
Weight (kg) 82.4 1.0 .28 79.2 1.2 .31 68.4 .9 .16 63.5 1.0 .27
BMI (kg/m2) 28.1 .3 .11 26.3 .4 .18 27.5 .4 .23 24.8 .4 .19
Waist-to-hip ratio .984 .005 .26 .946 .005 .06 .849 .005 .23 .809 .007 .19
Waist circumference (cm) 99.4 .8 .25 92.92 .88 .20 87.67 .93 .17 80.10 1.01 .10
Hip circumference (cm) 100.7 .5 .23 98.00 .50 .26 103.1 .7 .10 99.3 .7 .14
Thigh circumference (cm):
Proximal 58.2 .4 .28 57.20 .50 .27 58.8 .4 .10 59.0 .5 .28
Mid 43.4 .4 .27 52.60 .50 .23 52.8 .4 .04 52.4 .5 .30
Distal 40.9 .3 .20 39.90 .30 .25 40.6 .3 .07 39.9 .3 .38
Skinfold (mm):
Biceps 16.82 .96 .37 16.61 .98 .12 23.81 .84 .12 22.13 1.08 .07
Triceps 23.57 .94 .17 23.14 1.06 .07 34.25 .81 .29 30.22 .96 .10
Subscapular 25.81 .78 .15 22.81 .84 .15 28.22 .86 .40 24.24 1.03 .11
Suprailiac 24.90 .94 .41 21.81 1.02 .03 27.11 .74 .29 23.72 1.09 .08
Thigh 24.45 1.08 .35 26.84 1.27 .12 43.27 .89 .08 39.25 1.06 .05
Body fat (%):
Calculated 25.98 .39 .09 24.96 .49 .15 39.03 .42 .31 36.30 .61 .12
Derived 24.58 .56 .44 21.16 .69 .38 37.39 .77 .22 30.35 .82 .00
Cholesterol (mmol/liter):
Total 5.53 .09 .06 5.57 .09 .18 5.75 .08 .19 5.24 .08 .23
HDL 1.16 .03 .32 1.20 .02 .43 1.50 .03 .19 1.54 .03 .00
LDL 3.34 .07 .42 3.60 .09 .37 3.31 .07 .16 3.12 .07 .00
Triglycerides (mmol/liter) 2.40 .15 .12 1.86 .10 .21 1.98 .07 .25 1.29 .06 .29
Glucose (mmol/liter) 5.79 .12 .00 5.29 .07 .45 5.40 .07 .19 4.97 .08 .04
Creatinine (mmol/liter) 91.7 2.0 .13 85.9 .9 .03 70.8 1.1 .03 68.2 .9 .18
Uric acid (mmol/liter):
Plasma 356.5 5.6 .17 331.8 4.6 .25 295.2 4.6 .21 245.9 3.8 .29
Urinary 3.04 .22 .05 2.38 .30 .24 2.72 .27 .72 1.85 .19 .51
Glycerol (mmol/liter) .105 .028 .96 .053 .004 .04 .099 .004 .44 .080 .003 .18
Reactance (Q):
Ecw 567.0 5.2 .07 582.2 5.5 .27 677.4 6.5 .39 701.3 7.2 .41
Icw 1,027.2 14.4 .03 1,037.1 15.5 .38 1,407.4 20.5 .23 1,429.2 22.9 .46
Insulin (pmol/liter) 134.7 7.1 .11 114.5 4.6 .32 112.9 3.3 .04 103.4 2.6 .31
Arg-vaso (pg/ml)f 4.45 .17 .33 4.56 .19 .53 4.55 .16 .22 4.94 .17 .02
Renin, supine (ng/ml/h)f 1.23 .11 .61 1.77 .17 .31 1.25 .13 .17 1.35 .10 .41
NOTE.—Values in bold italics indicate between groups with and groups without high blood pressure (HBP); underlinedP  .001
values indicate correlation 0.25 (i.e., ). Familial correlation r was calculated with FCOR software.2h 1 50%
a Arg-vaso p arginine-vasopressin; Ecw p extracellular water; Icw p intracellular water.
b Maximum no. of sib pairs generated p 145.
c Maximum no. of sib pairs generated p 77.
d Maximum no. of sib pairs generated p 234.
e Maximum no. of sib pairs generated p 85.
f Measured in extensive phenotyping only.
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Table 2
Partitioning of Variance of a Set of Hemodynamic, Anthropometric, and Metabolic Traits
SOURCE OF VARIANCE
PERCENTAGE OF TOTAL VARIANCE (SQUARE ROOT OF VARIANCE) ATTRIBUTED TO MODELED EFFECTS
Residual Age Sex
Total Genetic
Variance
QTLsa Absolute
Total
VarianceFirst Second Other
SBP (mmHg) 44.2 (176.78) 18.3 (73.03) .7 (2.97) 36.8 (147.10) 20.8 (83.07) 11.9 (47.44) 4.1 (16.59) 399.88
DBP (mmHg) 66.7 (85.30) .8 (1.07) 5.1 (6.45) 27.4 (35.08) 18.0 (23.05) 6.7 (8.59) 2.7 (3.44) 127.90
Weight (kg)b 22.1 (53.38) 3.8 (9.26) 3.8 (9.20) 42.2 (101.89) 25.4 (61.20) 10.1 (24.45) 6.7 (16.24) 241.30
BMI (kg/m2) 37.6 (9.61) 1.0 (.25) 2.2 (.55) 59.2 (15.10) 31.5 (8.04) 16.3 (4.15) 11.4 (2.91) 25.50
Waist circumference (cm) 42.1 (91.63) 3.2 (7.02) 19.0 (41.24) 35.7 (77.52) 23.4 (50.63) 9.7 (21.09) 2.6 (5.80) 217.41
Skinfold subscapular (mm) 12.1 (16.24) .5 (.69) .3 (.37) 87.1 (116.85) 41.2 (55.32) 25.1 (33.69) 20.8 (27.84) 134.15
HDL cholesterolc (mmol/liter) 55.8 (.019) .8 (.000) 11.8 (.004) 31.6 (.011) 21.8 (.008) 8.1 (.003) 1.7 (.00) .0343
LDL cholesterol (mmol/liter) 48.9 (.513) 2.1 (.022) 1.1 (.012) 47.9 (.501) 20.1 (.211) 14.0 (.147) 13.8 (.143) 1.05
24-h urinary uric acidd (mmol/liter) 60.9 (.086) 1.7 (.002) 1.9 (.003) 35.5 (.050) 31.9 (.045) 3.0 (.004) .6 (.001) .142
Body fat by impedance (%) 22.2 (26.85) 18.9 (22.90) 23.6 (28.53) 35.3 (42.72) 20.6 (24.90) 10.2 (12.29) 4.5 (5.53) 121.00
a Ranked in order of variance contribution.
b Height was added as a covariate in the analysis. The contribution of height to the variance of weight was 28.1% (67.57 kg).
c Values are log10 HDL.
d Values are the square root of 24-h urinary uric acid.
important covariates for cardiovascular-related pheno-
types and that a sizable sexual dimorphism has to be
considered for several of these traits. The results pre-
sented in table 2 also confirmed the oligogenic and mul-
tifactorial nature of these traits, as demonstrated by the
relatively large contribution of both genetic (from a few
QTLs) and environmental (residual) factors to the var-
iance. For example, the percentage of residual contri-
bution to the variance of LDL levels was about the same
as the genetic contribution—that is, ∼48%.
BMI is the most often studied phenotype in the search
for genes underlying obesity-related traits. However, this
trait is a compound phenotype and, therefore, is unlikely
to provide accurate estimates. In addition to BMI, we
also analyzed weight and modeled height in the segre-
gation analysis. As expected, this strategy provided
lower estimates for residual variance. Most of the var-
iance of weight (78%) could thus be explained by the
effects modeled for QTLs, age, sex, and height. The con-
tribution of height to the variance of weight was ∼30%.
The genetic contribution for BMI was ∼60% compared
with ∼40% for weight adjusted for height, suggesting
that part of the genetic variance of BMI is due to the
genetic contribution of height. As defined in this data
set, the phenotypes of glucose and insulin plasma levels
did not show evidence for a genetic contribution (data
not reported).
Genomewide Linkage
The oligogenic character of most traits under study
was also evident from genomewide linkage analysis.
Whereas a total of 46 LOD scores 11.9 were detected
for the 213 BP, anthropometric, and metabolic traits
analyzed, several of them were found in QTL clusters,
particularly on chr 1, chr 3, chr 16, and chr 19 (fig. 4
and table 3). These clusters were analyzed further (see
fig. 5 for chr 1, fig. 6 for chr 3, fig. 7 for chr 16, and
fig. 8 for chr 19). A QTL cluster was defined as a chro-
mosomal region in which at least one trait had a LOD
score 12.0 and two additional traits with LOD scores
11.5 followed a similar pattern of linkage. When these
conditions were reached, we further analyzed additional
dependent and independent traits within the same chro-
mosomal region. On chr 1, the highest LOD scores were
reached for thigh circumferences (LOD of 3.8 between
markers D1S1677 and D1S2878) and BMI (LOD of 3.4
at D1S2762 at 175–180 cM). Among the metabolic
components, fasting insulin levels peaked at the same
location, with a LOD of 2.7 at marker D1S1679. Other
metabolic features, such as apolipoprotein A (apoA),
apoB, leptin, and cAMP levels, were also observed in
this region. Several skinfold phenotypes were local-
ized at a somewhat more telomeric location (210–215
cM): subscapular (LOD of 3.6 between D1S1660 and
D1S2622) and biceps (LOD of 3.4 at D1S2816), as were
global obesity measures: %body fat by skinfolds (LOD
of 3.1 at D1S2757), closely followed by %body fat by
impedance (LOD of 2.9 between D1S238 and D1S3468).
At an even further telomeric location (∼230 cM), several
DBP traits clustered, including a peak of average DBP
with a LOD of 2.1 at D1S2141 (fig. 6).
A second major cluster was detected on chr 3 at 170–
180 cM. A LOD of 2.6 was obtained for average DBP
(between D3S1763 and D3S3053). The narrow peak
reflected higher power, because phenotyping was con-
ducted in all subjects, whereas other traits required
the extensive phenotyping protocol described in the
“Methods and Procedures” section (Kotchen et al. 2000).
Thus, asleep DBP (determined by 24-h ambulatory BP
monitoring [ABPM]) reached a LOD of 2.0 between
D3S1746 and D3S1763, pre–math stress DBP LOD was
1.9 at D3S3053, 24-h awake DBP LOD was 1.5 at
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Table 3
Chromosomal Positions, Phenotypes, and Maximum
LOD Scores
The table is available in its entirety in the online edition
of The American Journal of Human Genetics.
Figure 4 Total-genome view of quantitative-trait linkage analysis by use of SOLAR in French Canadian families with hypertension
and/or dyslipidemia. Phenotypes with a LOD score 11.9 after 100,000 permutations are shown. For more details, see table 3.
D3S1763, and average supine DBP LOD was 1.4 at
D3S3053, whereas plasma renin while standing LOD
was 1.4 (between D3S3053 and D3S2427). Clearly, the
strength of these observations resided in the fact that
they all appeared in a common, relatively narrow chro-
mosomal segment in spite of having been measured un-
der largely different physiological conditions.
PCA and Bivariate Data Analyses
In analyzing the findings of this study, we were faced
with multivariate data recorded from extensive pheno-
typing. One of the approaches to deciphering the genetic
architecture of these multivariable phenotypes (Ghosh
and Majumder 2001) is PCA and bivariate analyses of
the results, as illustrated in figure 9. For the multiple
phenotypes present in the QTL clusters on chr 1 (fig. 5)
and chr 3 (fig. 6), PCA was done with the correlation
matrix of the phenotypes that were available on 1500
subjects. For the PCA for chr 1, we included phenotypes
mapping to the region with significant or suggestive
LOD scores (BMI; %body fat, determined by bioim-
pedance; biceps, subscapular, suprailiac, and triceps
skinfolds; and circumferences of proximal, middle, and
distal thigh). The correlation between principal com-
ponent factors and initial phenotypes was computed
first, and then linkage analysis was performed for both
factors, with principal component factor 1 mapping to
our initial linkage region on chr 1 with a LOD score of
4.9 at position 212 cM (fig. 9A shows a LOD plot for
all included phenotypes and factor 1). Bivariate analysis,
including that of BMI and glucose insulin, exceeded a
LOD of 5 at 175 cM on chr 1. For chr 3, in 130 subjects
not receiving medication, bivariate analysis of DBP mea-
sured before the mathematical test and average asleep
DBP derived from 24-h ABPM, we found a LOD sig-
nificantly higher than that for both univariate analyses
(LOD of 4.4), peaking at 173 cM. The same was true
for the results of bivariate analysis on chr 1, in which
combined BMI and insulin traits yielded a LOD of 5.1
at 173 cM.
Classification of Families on the Basis of Their LOD
Score Contributions
In complex traits, it is well known that clinical as well
as genetic heterogeneity greatly hampers the uncovering
of causal genomic factors. In our study population, in
spite of its relative homogeneity, genetic heterogeneity
was still clearly present. Although a heterogeneity-cor-
rected LODcor obtained by SOLAR has the capacity to
assess oligogenic traits, we sought additional tools to
reduce the impact of locus heterogeneity. We initially
deployed the LODcor obtained by SOLAR and then
ranked the families by density, as described in the “Meth-
ods and Procedures” section. This approach allowed the
ranking of families into CF, NCF, and ACF classes (il-
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Figure 5 Clusters of phenotypes illustrated by LOD curves for significant and suggestive QTLs on chr 1. A and B, Obesity-related
anthropometric phenotypes. A, BMI (black line) and circumferences of thigh proximal (blackened diamonds), thigh midway (gray diamonds),
thigh distal (unblackened diamonds), and upper arm (orange line with black dashes). B, Skinfolds: suprailiac (red line), subscapular (orange
line), biceps (yellow line), and triceps (pink line); and %body fat by impedance (blackened circles) and by skinfolds (unblackened circles). C,
Metabolic phenotypes: insulin (dark purple line), renin (blue line), leptin (blue circles), apoB (yellow line with black dashes), arginine-vasopressin
(turquoise line), apoA (green line), and cAMP 24-h excretion (light purple line). D, BP-related phenotypes: average DBP (green line), awake
DBP (green line with asterisks [*]), post–math stress DBP (blackened triangles), and mean awake BP (black line with asterisks [*]).
lustrated in fig. 1), providing the possibility of uncov-
ering loci contributing to a trait variance that would
have been missed by SOLAR analysis. Indeed, our
method is novel and was not previously published. To
evaluate the significance of the increase in LOD scores
from the baseline of 0.49 at this locus, we estimated the
probability of obtaining a LOD score of 5.82 by a ran-
dom selection of families. An empirical P value was com-
puted by performing two kinds of permutation tests. In
one test, the random variable is the set of CF, so we
compare 10,000 random sets of 25 families to see how
many times the subset generates a multipoint LOD score
at least as high as the maximum subset LOD score found
for CF. The P value is calculated on the basis of the
proportion of 10,000 random sets of families that gave
such a maximum subset LOD score. The highest LOD
score generated by this method was 3.97 (mean 0.23;
SD 0.35) with a corresponding P value !.0001. In the
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Figure 6 Clusters of phenotypes illustrated by LOD curves for
significant and suggestive QTLs on chr 3. Left panel, Sodium (yellow
line), renin (blue line), mean awake BP (black line), and asleep SBP
(red line with dashes). Right panel, DBP phenotypes: average (green
line), awake (green line with asterisks [*]), sleep (green line with
dashes), supine (green line with squares), and pre–math stress (green
line with blackened triangles).
Figure 7 Clusters of phenotypes illustrated by LOD curves for
significant and suggestive QTLs on chr 16.
other test, we randomly ordered all the families and,
beginning with the first-ranked family, we repeatedly
considered larger subsets (e.g., 1, 1_2, 1_2_3, …) and
computed the multipoint LOD score by adding the re-
maining families in order, one by one, until all families
were included. The highest LOD score obtained was
retained. The above operation was repeated 10,000
times, and the highest LOD score generated was 4.42
(mean 0.88; SD 0.44); thus, the P value was !.0001.
Twenty-thousand LOD score density analysis runs
were performed for the entire chr 1 specific to the cluster
illustrated in fig. 5, to ascertain the maximized LOD
score for BP. Although many metabolic traits were ob-
served in this cluster, only a modest contribution of BP
at the more telomeric position was found (fig. 5D). Mul-
tipoint maximization selection indeed uncovered a ro-
bust LOD score for SBP on chr 1 within the metabolic
cluster component. As seen in figure 10, whereas SOLAR
analysis of recumbent SBP gave a LOD of 0.5 at the
locus 195 cM on chr 1, 23 CF reached a LOD of 5.7,
and 21 ACF had a LOD of 0. This difference in LOD
scores translated into a 10-mmHg recumbent SBP phe-
notypic gradient between CF and ACF ( , withPp .007
age and sex as covariates).
Similar multipoint maximization selection was per-
formed for DBP on chr 3. Whereas the DBP QTL at 180
cM on chr 3, in the entire population, peaked at a LOD
of 1.2, analysis of 15 CF increased the LOD to 2.9, and
15 ACF had a LOD of 0, accounting for the 5.5-mmHg
DBP gradient between CF and ACF ( ). Fur-Pp .0003
ther analysis indicated that 22% of individuals from
seven CF overlapped between the two loci, giving a Jac-
quard coefficient of 22% and, in fact, that only five ACF
overlapped between loci on chr 2, yielding a Jacquard
coefficient of 16%. The Jacquard coefficient is defined
as —that is, is the ratioJ p FCF∩ ACFF/FCF∪ ACFF Jc c
of the cardinality of the union to that of the intersection
between CF and ACF. Phenotypic analysis of these CF
and ACF classes demonstrated that CF sharing maxi-
mized LOD scores on chr 1 and chr 3 and that CF
families, though bearing similar BP values to those of
ACF families, exhibited more obesity features, including
BMIs of 28 versus 24 ( ), waist circumferencesPp .0005
of 93 versus 78 ( ), supscapular skinfolds of 29Pp .002
versus 21 ( ), and %body fat of 26 versus 18Pp .003
( ) for CF versus ACF classes. A feature of met-Pp .01
abolic syndrome was thus apparent in 37% of CF and
9.6% of ACF classes.
Ancestral Separability of Families:
The Layered-Founders Approach
At this point in our study, we sought further evidence
for shared genetic determinants in the familial classes
described above. The eventual ancestral relatedness of
these families should constitute such an ascertainment.
One of the advantages of studying the French Canadian
population of the SLSJ region resides in the richness and
completeness of the genealogical data collected since the
beginning of the colony in 1608 and computerized in
the BALSAC population register (Bouchard et al. 1989).
We have used these genealogical data up to the depth
of 17 generations over 14 layers of founders (see the
“Methods and Procedures” section) to analyze the ge-
netic effect of ancestors in CF and ACF classes of living
subjects. The founder-effect measures vary from 0.6 to
0.7 at the most recent layer and from 0.8 to 0.9 at the
oldest layer. These figures indicate that the polarization
of genetic contribution is more pronounced at distant
generations and is more diluted (although still relevant)
at recent generations. Figure 11 illustrates that the an-
cestors of family classes contributing to BP QTLs on
either chr 1 or chr 3 displayed a specificity 190% within
the 3–4 most recent layers, and, even for the oldest lay-
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Figure 8 Clusters of phenotypes illustrated by LOD curves for
significant and suggestive QTLs on chr 19.
Figure 9 PCA and bivariate analyses of traits linked to chr 1
and chr 3. A, Linkage of principal component 1 (PC 1) (green line)
on chr 1, including BMI; %body fat (determined by bioimpedance);
skinfolds: biceps, subscapular, suprailiac, and triceps; and circumfer-
ences of proximal, middle, and distal thigh (for details on individual
linkage results, see fig. 5). B and C, Bivariate analyses for chr 1 and
chr 3. B, Univariate analyses of BMI (black line) and fasting insulin
(green line) and bivariate analysis (red line). C, Univariate analyses of
pre–math stress DBP (light blue line) and mean asleep DBP measured
by 24-h ABPM (dark blue line) and bivariate analysis (purple line).
ers, the expected drop maintained specificity between
∼55% and 85%. By observing founder-effect and spec-
ificity measures, one can note that these measures are
conceptually and experimentally distinct. In recent
layers, we discovered higher specificity and lower po-
larization, which indicates that genes are transmitted
through paths that intersect less than in older layers
(higher specificity), whereas the amount of contributions
is more similar among recent founders than among older
founders (lower polarization). A unique contribution to
each family class exceeded 90% for the three most recent
layers, and it was still 20%–30% of the most distant
ancestors (fig. 11A and 11C). Figure 11B and 11D de-
picts the separability of classes of founders, which is the
average differential contribution of separable founders
to family classes and which is 180% for the 3–4 most
recent layers, remaining at ∼40% for the most distant
founders. Separability indicates that, for recent genera-
tions, the genetic contributions of specific founders to
CF and to ACF differ by 180%, on average. For older
generations, such genetic contributions differ by 140%,
on average, which is still a wide gap in genetic contri-
bution. We then proceeded “back to the future” to re-
group the living descendants from the unique ancestors
of CF and ACF classes of chr 1 multipoint maximized
LOD at 195 cM. Within our cohort of 120 families,
after eliminating families with shared ancestral contri-
butions to individuals of both CF or ACF, we identified
25 families with 224 members with unique ancestors of
the CF class (streaming out from 66 genotyped subjects)
and 26 families with 213 members (62 genotyped in-
dividuals) for the ACF class. The SBP was 10 mmHg
higher in CF descendants than in ACF descendants
( ). These results permit the ascertainment ofPp .0009
relevance of family classes sharing both ancestor classes
and relevant phenotypes initially determined by their
maximized linkage at a specific locus.
Discussion
The oligogenic and epistatic character of complex dis-
eases makes the search for their genetic determinants a
challenging task (Lander and Schork 1994; Hamet et al.
1998; Doris 2002; Glazier et al. 2002; Samani 2003).
One of the approaches that has had some success is to
study relatively isolated human populations, such as the
Hutterites from South Dakota (Newman et al. 2003);
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Figure 10 Approximate gradient-driven LOD score density maximization. A, LOD scores at 195 cM on chr 1 for the SBP trait in families
classified by LOD score contribution. B, LOD scores at 180 cM on chr 3 for the average supine DBP trait in family classes. C, Family averages
of SBP in family classes at 195 cM on chr 1. D, Family averages of supine DBP in family classes at 180 cM on chr 3. Cp contributing families;
N p noncontributing families; A p anticontributing families. Letter combinations reflect the joining of families in the different groups (e.g.,
CNA p contributing, noncontributing, and anticontributing families combined).
the Finnish subpopulation from Koilliskaira, relatively
isolated since the sixteenth century (Woolley et al. 2002);
the Icelandic population analyzed by deCODE (Helga-
dottir et al. 2004); and the French Canadian population
investigated in the present study (Bouchard et al. 1989),
or to study populations of Mormons from Salt Lake City
because of their unifying religious, nutritional, and ge-
netic characteristics (Jeunemaıˆtre et al. 1992; O’Brien et
al. 1994; Scriver 2001). These populations offer several
advantages over the general population, including the
more uniform environment of their living conditions;
better mapping opportunities because of the longer link-
age disequilibrium intervals, as estimated by the genetic
clock (Labuda et al. 1997); and, most importantly, access
to their genealogical records (Peltonen et al. 2000). The
design and analyses performed in the present investi-
gation were aimed at addressing several of the issues
that often cause failure to identify genetic factors re-
sponsible for the phenotypic variation of complex traits
(Rice et al. 2000; Glazier et al. 2002; Samani 2003).
We have applied an extensive phenotyping protocol
(Kotchen et al. 2000, 2002; Pausova et al. 2000) to a
relatively homogeneous population, which led to the
highest number of loci contributing to cardiovascular-
related and metabolic traits reported to date. Selection
of the proband sib pair, on the basis of the presence of
hypertension and dyslipidemia (25% of subjects in-
cluded in the present study exhibited metabolic syn-
drome features based on ATPIII criteria), permitted us
to map several components of the metabolic syndrome,
particularly on chr 1 and chr 3. The application of a
battery of classic and more-novel statistical analytical
tools, including Bayesian MCMC–based oligogenic seg-
regation analysis, as well as bivariate analysis and PCA,
resulted in the identification of highly significant linkage
groups for several phenotypes. Bivariate analysis and
PCA were performed only for traits that mapped at the
same location and showed significant or suggestive link-
age in a single-trait analysis, since one can assume that
these traits might have a common genetic component
and/or a common gene influencing the traits jointly. In
view of the extensive phenotyping, we first assessed the
feasibility of detecting and localizing QTLs that underlie
the collected phenotypes, by use of Bayesian MCMC
segregation analysis. This analysis suggested the pres-
ence of QTLs with a large effect for several phenotypes
(table 2). As highlighted by Beaumont and Rannala
(2004), Bayesian methods such as those used for our
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Figure 11 A and B, Founders’ specific (squares) and unique (circles) genetic contributions to family classes, which are either contributing
(blackened squares and circles) or anticontributing (unblackened squares and circles) to the LOD score. C and D, Overall separability of CF
versus ACF over 14 generational layers at the corresponding loci. E and F, Founder effect (squares) and specific normalized founder effect
(circles) in CF (blackened squares and circles) and ACF (unblackened squares and circles). A–C, SBP trait at 195 cM on chr 1. C–E, Average
supine DBP trait at 180 cM on chr 3.
segregation analysis have numerous advantages over
classic approaches, and one can foresee their use in an
increasing number of areas of genetic analysis. Our sub-
sequent linkage analysis and the identification of signif-
icant and suggestive QTLs further support these find-
ings. Although it has been initially suggested that
variance-components linkage analysis allows for the es-
timation of locus-specific variance, on the basis of sim-
ulation studies, this is considered imprecise, and there-
fore we report only LOD scores, to avoid a large upward
bias in the estimation of locus-specific effects, with re-
gard to the comments by Go¨ring et al. (2001) and Sieg-
mund (2002). Thus, Bayesian segregation analysis al-
lowed orientation toward phenotypes that exhibited (1)
a significant genetic contribution and (2) a restricted
number of major loci (see table 2). LOD score density
analysis permitted the separation of family groups un-
derlying the phenotypic gradient, exemplified in figure
10 and further confirmed by the genealogical studies
discussed below.
In the French Canadian population, the most prom-
inent clusters of QTLs for hemodynamic, anthropo-
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metric, and metabolic phenotypes were found on chr 1
and chr 3. Two clusters regrouping 120 QTLs peaked
at 175 cM and 210 cM on chr 1, respectively, corre-
sponding to QTLs already identified in diverse ethnic
groups, including our hypertensive African American
sib pairs (Kotchen et al. 2002), and in studies of the
genetics of the metabolic syndrome (Langefeld et al.
2004) and type 2 diabetes (Hanson et al. 1998). One
of the strengths of the current investigation is the ro-
bustness and comprehensiveness of the phenotyping,
since, for any given attribute of the metabolic syndrome,
a whole battery of endophenotypes was recorded (e.g.,
for obesity, three different global phenotypes—BMI and
%body fat by impedance and by skinfold—and nine
regional obesity measures were all significantly linked
to the two subregions of the chr 1 cluster).
Although a BP QTL has been reported elsewhere in
Finnish twins (Perola et al. 2000), the mapping of eight
BP phenotypes (in addition to renin levels and urinary
sodium excretion) at 150–200 cM on chr 3 in the cur-
rent study enriched our understanding of the contri-
bution of this segment of chr 3 by the fact that a shared
QTL was obtained for BP values determined under a
variety of physiological conditions, such as wakefulness,
sleep, before and after stress, or time-series averaged for
longer periods of time. Interestingly, BP QTLs colocal-
ized with renin and sodium QTLs on chr 3, suggesting
common pathways for these traits, whereas anthropo-
metric traits colocalized with insulin levels on chr 1.
The notion of shared pathways was supported by the
results of PCA and bivariate analyses (see fig. 9).
The evidence of linkage, even if reaching significant
levels (i.e., LOD of 3.9 for subscapular skinfold on chr
1) and even if corroborated by several independently
assessed traits, is not definitive proof of the presence of
genetic determinants underlying the observed trait var-
iance. We thus used a novel method of classifying fam-
ilies on the basis of LOD score density analysis, which
enabled us to identify families that are likely to harbor
susceptible/causal haplotypes. This method is somewhat
reminiscent of another approach to decreasing hetero-
geneity, developed recently by Hauser et al. (2004a,
2004b), that ranks phenotypes prior to LOD compu-
tation. This stratification by phenotypes allowed those
investigators to uncover, among others, a QTL for mac-
ular degeneration, specifically in hypertensive subjects.
It is of interest that we have also observed a significant
BP cluster on chr 16 (see fig. 7). Nevertheless, our
method of “ranking” is aimed at decreasing heteroge-
neity at the family level by ranking their LOD score
contribution. We believe that both methods will have a
specific use in dissecting complex traits.
The completeness of the genealogical data of the an-
cestors of currently living families in the SLSJ area (Bou-
chard et al. 1989; Heyer and Tremblay 1995) and the
concept of layered founders (E. Merlo, B. Deslauriers,
G. Antoniol, P. L. Brunelle, M. Jomphe, G. Bouchard,
O. Seda, U. Broeckel, A. W. Cowley Jr., J. Tremblay,
and P. Hamet, unpublished data) permitted us to eval-
uate the extent of shared familial contribution within
ancestral lineage. Classes of CF, impacting QTL LOD
scores and thus sharing a specific locus, presented a
phenotypic gradient, compared with classes of ACF (fig.
10). Families sharing maximized LOD on chr 1 and chr
3 shared obesity/metabolic phenotypes. We then ana-
lyzed family classes for their ancestral separability. In-
deed, as illustrated in figure 11, we found significant
separability of founders between these contrasting fam-
ily classes, even to the depth of 14 layers (17 genera-
tions). Moreover, families contributing to the linkage of
metabolic syndrome–related phenotypes on chr 1 were
largely distinct from families whose BP determinants
resided on chr 3. These distinctions would have been
missed if heterogeneity had not been reduced by re-
grouping the families into specific classes. The last step
included the reverse path from unique ancestors to their
living descendants. Indeed, thus regrouped, families ini-
tially selected along maximized LOD and phenotypic
gradient, then separated for uniquely contributing an-
cestors, bear significant differences in both SBP and DBP
in living descendents.
The term “founder effect” is usually applied to Men-
delian diseases in expanding, isolated populations. The
effect is due to an increase in the frequency of certain
alleles, causing a phenotype with relatively little clinical
variation. In French Canadians of the SLSJ area, this
has been the case for some monogenic dominant and
recessive disorders (Scriver 2001). In complex disorders,
the situation is a Gordian knot, but certain allele fre-
quencies still may change if, by chance, they were over-
or underrepresented among the first settlers who most
impacted the population gene pool. It has been esti-
mated that ∼70% of today’s SLSJ population gene pool
has descended from the first three migration waves (La-
buda et al. 1996). The changes in common allele fre-
quencies are proportional to those in the outbred pop-
ulation and are thus much less drastic for common than
for rare variants. The observation of ancestry sharing,
in families contributing to QTLs on chr 1 (for example),
corroborate well with the expected overrepresentation
of some alleles at certain loci—in this case, cardiovas-
cular susceptibility variants. The chr 1q region is one
of the most commonly reported in the literature as being
linked with cardiovascular diseases and likely carrying
multiple genes with multiple variants, increased in fre-
quency by the stochastic process in the SLSJ region.
The founder effect in our study has been observed
over several generations and classes of living individu-
als. Our quantitative genealogical approach supports
the notion of the ancestral causality of traits uniquely
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present and inherited in distinct family classes. We pro-
pose the “quantitative founder effect” in which a trait
determined within population subsets is measurably and
quantitatively transmitted throughout generational lin-
eage, contributing to a precise component of phenotypic
variance.
We believe that the application of these methods,
which are particularly relevant for relatively homoge-
neous populations, enriched by the presence of well-
documented genealogical records, will accelerate the
uncovering of causal haplotypes (Daly et al. 2001) in
diseases as complex as hypertension and the metabolic
syndrome.
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